Menveo vaccine approved for meningococcal disease immunization
In study participants aged 11–18 years, the percentages of subjects who demonstrated an immune response (ie, achieved an hSBA titer ≥1:8) for each serogroup for Menveo and its comparators respectively, were: serogroup A – 75%:67%; serogroup C – 84%:84%; serogroup Y – 88%:69%; and serogroup W-135 – 96%:88%. The seroresponse with Menveo for serogroups A, Y and W-135, was statistically higher. However the clinical relevance of higher post-vaccination immune responses is not known.
Menveo is expected to be available by the end of March 2010.For more information call (617) 871-5500 or visit www.novartisvaccines.com.